Chapter 8 Atherogenic Lipoprotein Subprofiling

Advances in Clinical Chemistry

Volumn 46, Issue , 2008, Pages 295-317

  Ellington, Allison A ^a   Kullo, Iftikhar J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL; ATHEROSCLEROSIS; BLOOD; CHEMISTRY; CLASSIFICATION; CORONARY ARTERY DISEASE; ELECTROPHORESIS; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHYSIOLOGY; REVIEW; ULTRACENTRIFUGATION;

ANIMALS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CHOLESTEROL, LDL; CORONARY DISEASE; ELECTROPHORESIS; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; ULTRACENTRIFUGATION;

EID: 53849134495     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(08)00408-3     Document Type: Review

References (109)

1. Ross R. Atherosclerosis-an inflammatory disease. NEJM 340 (1999) 115-126
2. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
3. Barter P.J., Ballantyne C.M., Carmena R., Castro Cabezas M., Chapman M.J., and Couture P. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
4. Rizzo M., and Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 99 (2006) 1-14
5. Ginsberg H.N. Lipoprotein physiology. Endocrinol Metab Clin North Am 27 (1998) 503-519
6. Bolanos-Garcia V.M., and Miguel R.N. On the structure and function of apolipoproteins: More than a family of lipid-binding proteins. Prog Biophys Mol Biol 83 (2003) 47-68
7. Alaupovic P. The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Curr Atheroscler Rep 5 (2003) 459-467
8. Cham B.E. Importance of apolipoproteins in lipid metabolism. Chem Biol Interact 20 (1978) 263-277
9. Gilbert-Barnes E., Barnesss L., and Olsen R. Disorders of lipoprotein metabolism. Metabolic Diseases: Foundations of Clinical Management, Genetics and Pathology (2000), Eaton Publishing, Natick (MA) 283-322
10. Lackner C., Cohen J.C., and Hobbs H.H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 2 (1993) 933-940
11. Koschinsky M.L. Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein. Curr Atheroscler Rep 7 (2005) 389-395
12. Krauss R.M. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J 113 (1987) 578-582
13. Krauss R.M., and Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23 (1982) 97-104
14. Packard C.J., and Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17 (1997) 3542-3556
15. Brown M.S., and Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986) 34-47
16. Fielding C.J., and Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res 36 (1995) 211-228
17. Soumian S., Albrecht C., Davies A.H., and Gibbs R.G. ABCA1 and atherosclerosis. Vasc Med 10 (2005) 109-119
18. Santamarina-Fojo S., Lambert G., Hoeg J.M., and Brewer Jr. H.B. Lecithin-cholesterol acyltransferase: Role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 11 (2000) 267-275
19. Klerkx A.H., El Harchaoui K., van der Steeg W.A., et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: Pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol 26 (2006) 706-715
20. Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 31 (2003) 1066-1069
21. Millar J.S., and Packard C.J. Heterogeneity of apolipoprotein B-100-containing lipoproteins: What we have learnt from kinetic studies. Curr Opin Lipidol 9 (1998) 197-202
22. Goldberg I.J. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37 (1996) 693-707
23. Zambon A., Hokanson J.E., Brown B.G., and Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density. Circulation 99 (1999) 1959-1964
24. Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 31 (2003) 1066-1069
25. Patsch J.R., Prasad S., Gotto Jr. A.M., and Patsch W. High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 80 (1987) 341-347
26. Nigon F., Lesnik P., Rouis M., and Chapman M.J. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 32 (1991) 1741-1753
27. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
28. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
29. Malle E., Marsche G., Panzenboeck U., and Sattler W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: Fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 445 (2006) 245-255
30. Navab M., Berliner J.A., Subbanagounder G., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 (2001) 481-488
31. Chisolm III G.M., Hazen S.L., Fox P.L., and Cathcart M.K. The oxidation of lipoproteins by monocytes-macrophages. Biochemical and biological mechanisms. J Biol Chem 274 (1999) 25959-25962
32. Chinetti G., Gbaguidi F.G., Griglio S., et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101 (2000) 2411-2417
33. Kullo I.J., Edwards W.D., and Schwartz R.S. Vulnerable plaque: Pathobiology and clinical implications. Ann Intern Med 129 (1998) 1050-1060
34. Stamler J. George lyman duff memorial lecture. Lifestyles, major risk factors, proof and public policy. Circulation 58 (1978) 3-19
35. Anand S.S. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Vasc Med 8 (2003) 289-290
36. Castelli W.P. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol 4 Suppl. A (1988) 5A-10A
37. Otvos J.D., Jeyarajah E.J., and Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90 (2002) 22i-29i
38. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
39. Bucolo G., and David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19 (1973) 476-482
40. Allain C.C., Poon L.S., Chan C.S., Richmond W., and Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem 20 (1974) 470-475
41. Bachorik P.S., and Ross J.W. National Cholesterol Education Program Recommendations on Lipoprotein Measurement from the National Cholesterol Education Program Recommendations on Lipoprotein Measurement (1995), National Heart, Lung, and Blood Institute, Bethesda, MD
42. Scharnagl H., Nauck M., Wieland H., and Marz W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 39 (2001) 426-431
43. Bray G.A., and Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29 (2006) 109-117
44. Rubies-Prat J., Reverter J.L., Senti M., et al. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 16 (1993) 1081-1086
45. Hirany S., Li D., and Jialal I. A more valid measurement of low-density lipoprotein cholesterol in diabetic patients. Am J Med 102 (1997) 48-53
46. Matas C., Cabre M., La Ville A., et al. Limitations of the Friedewald formula for estimating low-density lipoprotein cholesterol in alcoholics with liver disease. Clin Chem 40 (1994) 404-406
47. Joven J., Villabona C., Vilella E., Masana L., Alberti R., and Valles M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323 (1990) 579-584
48. Rajman I., Harper L., McPake D., Kendall M.J., and Wheeler D.C. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 13 (1998) 2281-2287
49. Shoji T., Ishimura E., Inaba M., Tabata T., and Nishizawa Y. Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 38 (2001) S30-S33
50. Legault C., Stefanick M.L., Miller V.T., Marcovina S.M., and Schrott H.G. Effect of hormone replacement therapy on the validity of the Friedewald equation in postmenopausal women: The Postmenopausal Estrogen/Progestins Interventions (PEPI) trial. J Clin Epidemiol 52 (1999) 1187-1195
51. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., and Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
52. Austin M.A., King M.C., Vranizan K.M., and Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82 (1990) 495-506
53. Kullo I.J., de Andrade M., Boerwinkle E., McConnell J.P., Kardia S.L.R., and Turner S.T. Pleiotropic genetic effects contribute to the correlation between HDL cholesterol, triglycerides, and LDL particle size in hypertensive sibships. Am J Hypertens 18 (2005) 99-103
54. Kullo I.J., Ding K., Boerwinkle E., Turner S.T., and de Andrade M. Quantitative trait loci influencing low density lipoprotein particle size in African Americans. J Lipid Res 47 (2006) 1457-1462
55. Rizzo M., Barbagallo C.M., Severino M., et al. Low-density-lipoprotein peak particle size in a Mediterranean population. Eur J Clin Invest 33 (2003) 126-133
56. Campos H., Blijlevens E., McNamara J.R., et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb 12 (1992) 1410-1419
57. Nordestgaard B.G., and Nielsen L.B. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 5 (1994) 252-257
58. Bjornheden T., Babyi A., Bondjers G., and Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123 (1996) 43-56
59. Camejo G., Rosengren B., Olson U., et al. Molecular basis of the association of arterial proteoglycans with low density lipoproteins: Its effect on the structure of the lipoprotein particle. Eur Heart J 11 Suppl. E (1990) 164-173
60. de Graaf J., Hak-Lemmers H.L., Hectors M.P., Demacker P.N., Hendriks J.C., and Stalenhoef A.F. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11 (1991) 298-306
61. Tribble D.L., Rizzo M., Chait A., Lewis D.M., Blanche P.J., and Krauss R.M. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 110 (2001) 103-110
62. Cromwell W.C., and Otvos J.D. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6 (2004) 381-387
63. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25 (2005) 553-559
64. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955) 1345-1353
65. Schumaker V.N., and Puppione D.L. Sequential flotation ultracentrifugation. Methods Enzymol 128 (1986) 155-170
66. Chung B.H., Segrest J.P., Cone J.T., Pfau J., Geer J.C., and Duncan L.A. High resolution plasma lipoprotein cholesterol profiles by a rapid, high volume semi-automated method. J Lipid Res 22 (1981) 1003-1014
67. Kulkarni K.R., Garber D.W., Marcovina S.M., and Segrest J.P. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 35 (1994) 159-168
68. Kulkarni K.R., Garber D.W., Jones M.K., and Segrest J.P. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J Lipid Res 36 (1995) 2291-2302
69. Bautovich G.J., Dash M.J., Hensley W.J., and Turtle J.R. Gradient gel electrophoresis of human plasma lipoproteins. Clin Chem 19 (1973) 415-418
70. Gambert P., Farnier M., Bouzerand C., Athias A., and Lallemant C. Direct quantitation of serum high density lipoprotein subfractions separated by gradient gel electrophoresis. Clin Chim Acta 172 (1988) 183-190
71. Rainwater D.L. Electrophoretic separation of LDL and HDL subclasses. Methods Mol Biol 110 (1998) 137-151
72. Tsukamoto H., Takei I., Ishii K., and Watanabe K. Simplified method for the diameter sizing of serum low-density lipoprotein using polyacrylamide gradient gel electrophoresis. Clin Chem Lab Med 42 (2004) 1009-1012
73. Hoefner D.M., Hodel S.D., O'Brien J.F., et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 47 (2001) 266-274
74. Hirany S.V., Othman Y., Kutscher P., Rainwater D.L., Jialal I., and Devaraj S. Comparison of low-density lipoprotein size by polyacrylamide tube gel electrophoresis and polyacrylamide gradient gel electrophoresis. Am J Clin Pathol 119 (2003) 439-445
75. Burstein M., and Morlin R. [Precipitation of serum lipoproteins by anionic detergents in the presence of bivalent cations]. Rev Eur Etud Clin Biol 15 (1970) 109-113
76. Gidez L.I., Miller G.J., Burstein M., Slagle S., and Eder H.A. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 23 (1982) 1206-1223
77. Hirano T., Ito Y., and Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb 12 (2005) 67-72
78. Hirano T., Ito Y., Saegusa H., and Yoshino G. A novel and simple method for quantification of small, dense LDL. J Lipid Res 44 (2003) 2193-2201
79. Otvos J.D., Jeyarajah E.J., Bennett D.W., and Krauss R.M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38 (1992) 1632-1638
80. Ensign W., Hill N., and Heward C.B. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 52 (2006) 1722-1727
81. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
82. Rosenson R.S., Otvos J.D., and Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 90 (2002) 89-94
83. Blake G.J., Otvos J.D., Rifai N., and Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106 (2002) 1930-1937
84. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 94 (1996) 273-278
85. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 358 (2001) 2026-2033
86. Moss A.J., Goldstein R.E., Marder V.J., et al. Thrombogenic factors and recurrent coronary events. Circulation 99 (1999) 2517-2522
87. Corsetti J.P., Zareba W., Moss A.J., and Sparks C.E. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis 177 (2004) 367-373
88. Talmud P.J., Hawe E., Miller G.J., and Humphries S.E. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 22 (2002) 1918-1923
89. Jiang R., Schulze M.B., Li T., et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27 (2004) 1991-1997
90. Pischon T., Girman C.J., Sacks F.M., Rifai N., Stampfer M.J., and Rimm E.B. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005) 3375-3383
91. Kuller L., Arnold A., Tracy R., et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22 (2002) 1175-1180
92. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
93. Walldius G., and Jungner I. Apolipoprotein B and apolipoprotein A-I: Risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 255 (2004) 188-205
94. Williams K., Sniderman A.D., Sattar N., D'Agostino Jr. R., Wagenknecht L.E., and Haffner S.M. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 108 (2003) 2312-2316
95. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001) 1108-1113
96. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106 (2002) 2526-2529
97. Sniderman A., Vu H., and Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis 89 (1991) 109-116
98. Durrington P.N., Bolton C.H., and Hartog M. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta 82 (1978) 151-160
99. Noma A., Hata Y., and Goto Y. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: Reference values, and age- and sex-related differences. Clin Chim Acta 199 (1991) 147-157
100. Marcovina S.M., Albers J.J., Dati F., Ledue T.B., and Ritchie R.F. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 37 (1991) 1676-1682
101. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., and Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 40 (1994) 586-592
102. Sattar N., Williams K., Sniderman A.D., D'Agostino Jr. R., and Haffner S.M. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 110 (2004) 2687-2693
103. Genest J., Frohlich J., Fodor G., and McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. Cmaj 169 (2003) 921-924
104. Leiter L.A., Mahon J., and Ooi T.C. Macrovascular complications, dyslipidemia, and hypertension. Can J Diabetes 27 (2003) S58-S65
105. Kostner K.M., and Kostner G.M. Lipoprotein(a): Still an enigma. Curr Opin Lipidol 13 (2002) 391-396
106. Danesh J., Collins R., and Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
107. Luc G., Bard J.M., Arveiler D., et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis 163 (2002) 377-384
108. Marcovina S.M., Albers J.J., Gabel B., Koschinsky M.L., and Gaur V.P. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 41 (1995) 246-255
109. Marcovina S.M., and Koschinsky M.L. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 82 (1998) 57U-66U